Subscribe To Our Free Newsletter |
Dr Reddy’s Labs slumps 5% as brokerages give ‘Reduce’ call post Q4 earnings
The miss was driven by lower Revlimid sales, muted growth across markets and higher R&D spends. While the prevailing US tailwinds provide stability, absence of any meaningful approvals for Dr Reddy's